Abstract
56 boys, aged 9.2 - 17.8 years, with height deviation for age (HD) (mean±SD) -2.6 ± 0.8 SD, lag in Greulich-Pyle bone age (BA) 2.7 ± 0.9 years, and height deviation for BA corrected according to a longitudinal Finnish study (IPH, index of potential height) −0.9 ± 0.8 SD, were given fluoxymesterone 0.13 ± 0.05 mg/kg daily (dose increasing with BA) for 1.0 ± 0.4 years, minimum 0.4 years. Growth velocity during treatment was greater (p<0.001) both in boys with initial BA =10 years (group I, N=16, 7.5 ± 0.8 cm/year) and in boys with initial BA > 10 years (group II, N=40, 9.0 ± 1.3 cm/year) compared with similar control groups (N=15 and 36, velocity 4.1 ± 1.4 and 6.1 ± 2.1 cm/year, respectively). ΔHD was 0.4 ± 0.3 SD during treatment against 0.1 ± 0.4 SD in controls (p<0.01). ΔIPH for group I was −0.4 ± 0.6 SD against −0.4 ± 0.6 SD in controls, and for group II 0.2 ± 0.3 SD against 0.0 ± 0.3 SD in controls (p<0.02). 8 boys of group I and 21 boys of group II had a follow-up >0.4 years after treatment and their total ΔIPH was −0.7 ± 1.4 SD and 0.2 ± 0.3 SD, respectively. The size of testes clearly increased during treatment in 2/3 of the boys. Of plasma gonadotrophins FSH decreased from pretreatment levels after 4 - 6 months treatment, LH showed no significant change. 3 boys of group I had frequent erections or appearance of pubic hair. Our mode of treatment brings about an acceleration of growth and maturation. In boys with BA >10 years its mean effect on final height is a slight increase. In younger boys this effect is uncertain and it may not be wise to treat boys prior to BA 10 years.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mäenpää, J., Lenko, H. & Perheentupa, J. 99: Evaluation of fluoxymesterone treatment of slow growth and maturation. Pediatr Res 10, 886 (1976). https://doi.org/10.1203/00006450-197610000-00090
Issue Date:
DOI: https://doi.org/10.1203/00006450-197610000-00090